Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has recruited the first patient for its Phase 2B MDMA-assisted therapy trial for post-traumatic stress disorder (PTSD).

The EMDMA-001 trial has been designed to assess the safety, efficacy and cost-effectiveness of MDMA-assisted therapy for PTSD.

It aims to generate vital data that will strengthen Emyria's position as a leader in providing psychedelic-assisted therapy within a comprehensive multidisciplinary clinical service.

The news comes soon after Emyria announced it was acquiring the Pax Centre, Australia’s leading multidisciplinary psychological trauma care service.

It brings a top-tier clinical service into the EMD fold, expanding its capabilities as it develops therapies to meet a burgeoning market.

A report from InsightAce Analytics expects the total addressable market for psychedelic assisted therapies to reach US$8.31 billion by 2028.

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com